RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients
Stock Information for Redhill Biopharma Ltd.
Loading
Please wait while we load your information from QuoteMedia.